Sen­sei and In­stil Bio let go large chunks of work­forces, shift pipelines

Clin­i­cal tri­al dis­ap­point­ments have led Sen­sei Bio­ther­a­peu­tics and In­stil Bio to lay off 40% and 60% of em­ploy­ees, re­spec­tive­ly.

A tri­al flop on its lead …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER